PM&R Meeting Abstracts

Official abstracts site for the AAPM&R Annual Assembly and the PM&R Journal.

MENU 
  • Home
  • Meetings Archive
    • AAPM&R Annual Assembly 2022
    • AAPM&R Annual Assembly 2021
    • AAPM&R Annual Assembly 2020
    • AAPM&R Annual Assembly 2019
  • Resources
  • Advanced Search

Necrotizing Autoimmune Myopathy Diagnosed by EMG

Vaibhav Batheja, DO (New York University Grossman School of Medicine PM&R Program, New York City, New York); Martin Pico, MD

Meeting: AAPM&R Annual Assembly 2021

Categories: General Rehabilitation (2021)

Session Information

Session Title: AA 2021 Virtual Posters - General Rehabilitation

Session Time: None. Available on demand.

Disclosures: Vaibhav Batheja, DO: No financial relationships or conflicts of interest

Case Diagnosis: EMG aiding in the diagnosis of necrotizing autoimmune myopathy.

Case Description: A 72-year-old male with a history of HIV and chronic deep vein thrombosis presented with a three-month history of lower extremity weakness and subjective difficulty in ambulation. Initial exam was unremarkable aside from mild atrophy and 4/5 strength on muscle testing in the bilateral proximal lower extremities. Lab work was significant for an elevated creatine phosphokinase level of 4,865 prompting early neurophysiology consultation for electrodiagnostics studies. Motor nerve conduction studies of the bilateral peroneal and tibial nerve CMAPs showed normal latencies, normal conduction velocities and normal amplitudes except for a mildly decreased right tibial nerve amplitude. Sensory studies were normal. Electromyography (EMG) demonstrated multiple muscles in the lower extremities with moderate membrane instability, short duration motor unit action potentials, and an early recruitment pattern compatible with a myopathic process. Given concern for inflammatory myopathy, the patient was referred to rheumatology. Additional lab work demonstrated positive anti-HMGCoA antibodies. Further investigation of the patient’s medications revealed Tenofovir as the likely cause of the patient’s necrotizing autoimmune myopathy.

Setting: OutpatientAssessment/

Results: The medication, Tenofovir, was held with clinical resolution of his symptoms as well as normalization of creatine phosphokinase level after four weeks.

Discussion: Electrodiagnostic testing should be considered for further evaluation in patients with progressive weakness and an elevated creatine phosphokinase. EMG findings positive for a myopathic process should be followed up with rheumatologic workup, which can definitively diagnose necrotizing autoimmune myopathy. Although statins are the most common offending medication, other medications including HIV antivirals can be the source.

Conclusion: Medications can induce a necrotizing autoimmune myopathy which is characterized by myopathic process on EMG, and lab work demonstrating an elevated creatine phosphokinase. Although statins are the most common source in literature, other medications such as HIV antiretrovirals should also be judiciously considered.

Level of Evidence: Level V

To cite this abstract in AMA style:

Batheja V, Pico M. Necrotizing Autoimmune Myopathy Diagnosed by EMG [abstract]. PM R. 2021; 13(S1)(suppl 1). https://pmrjabstracts.org/abstract/necrotizing-autoimmune-myopathy-diagnosed-by-emg/. Accessed May 21, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to AAPM&R Annual Assembly 2021

PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/necrotizing-autoimmune-myopathy-diagnosed-by-emg/

Leading the Way. Baltimore, MD & Virtual. October 20-23, 2022. #aapmr22

PM&R Journal

View issues of PM&R on the Wiley Online Library »

American Academy of Physical Medicine and Rehabilitation

Visit the official site for the American Academy of Physical Medicine and Rehabilitation »

AAPM&R Annual Assembly

Visit the official site for the AAPM&R Annual Assembly »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
Wiley